Bristol University spin-out Apitope develops promising treatment for multiple sclerosis.

Apitope, a life sciences spin-out from Bristol University, has announced a promising new drug for treatment of multiple sclerosis (MS).

The drug, which treats the underlying cause of MS, halts progress of the disease, and showed improvements in 43 of the 49 patients treated.

Following completition of its Phase I trial, the company has licensed the drug to Merck Serano, the biopharmaceutical division of Merck KG, for Phase II trials.

Keith Martin, chief executive of Apitope, said: “We are pleased…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?